awmsg logo



lanreotide (Somatuline® Autogel®)


Reference No. 1988

Publication date:
25/09/2018


Appraisal information

lanreotide (Somatuline® Autogel®) 120 mg solution for injection


Company: Ipsen Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 11/07/2018
AWMSG meeting date: 12/09/2018
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1418
Ratification by Welsh Government: 20/09/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Lanreotide (Somatuline® Autogel®) is recommended as an option for use within NHS Wales for the treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download